Ascletis announced that the global Phase III clinical program for the once-daily oral administration of the small molecule GLP-1 receptor agonist ASC30 for chronic weight management has completed the first patient administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.